Changing the treatment method from the basic
We have newly developed a mobile-type dosing and intravenous device “atDose” (patented)
Developer:Yodaka Giken Co., Ltd.
With this device, we aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases such as cancer.
As for conventional dosing methods, 85% of the medicines are taken orally. Other than that, there are intravenous injections, subcutaneous injections, infusions, paints, and adhesives.
The components of the drug taken are absorbed into the body from the epithelial cells of the small intestine via the mouth → esophagus → stomach → small intestine, and reach the liver through a bundle of blood vessels called the hepatic portal vein.
The components of the medicine taken are not all in the body due to the effects of gastric acid degradation, absorption efficiency by the small intestine, etc., but part of it passes through the liver and reaches the whole body. Ingredients are decomposed and metabolized to a small amount, and then some components reach the affected area while riding on the blood and going through the whole body. Therefore, the stronger the drug, the more strain on the liver, leading to liver disease, and the higher the blood concentration, the greater the risk of side effects. Currently, there is an inefficient method of administering 100 doses and delivering only 1 to the affected area (excluding systemic symptoms such as antibiotics for the treatment of infectious diseases). Each major pharmaceutical company holds hundreds of thousands of ingredients (compound library), but in the case of medication or intravenous injection as described above, it is necessary to administer more than the amount necessary for actual treatment. As a result, the toxicity and side effects are stronger than the therapeutic effects, and it is not possible pass clinical tests to obtain approval. This is the root cause of the difficulty in finding new drugs.
In order to solve this problem, we have combined an ultra-fine and long injection needle as thick as a hair with a pump capable of continuous liquid feeding with an ultra-fine liquid volume, surrounded by an elastomer (rubber) to prevent liquid leakage. We have newly developed a lightweight portable intravenous device (mobile dosing / infusion device). By using this, a fine needle is directly inserted into the affected area, and the drug is effective only on the affected area (tumor/specific organ) by controlling the amount of ultra-fine liquid. We believe that we can do this and promote this project. In addition, we have received support from several university pharmacies, medical schools, hospitals, and public research institutions.
In addition, it can be applied to various diseases because it can be treated locally and with less pain.
Then, there are two reasons why we have not come up with such an idea until now.
- There was no easy pump that could be controlled with ultra-fine liquid volume
- There were no thin and long needles that would not cause any problems even if they were deeply stabbed directly into the affected area from the skin.
The following is a comparison of the pumps developed by our company and the existing smallest pumps of other companies.
No matter what size (volume), weight, price, vibration, pulsating flow, flow velocity, power consumption, etc. are compared, nothing else beat us. In addition, since the whole thing is covered with elastomer, the risk of liquid leakage can be reduced to the utmost limit, and there is no risk of liquid medicine leakage or electric short circuit.
For extra-fine needles, use an outer diameter of 100 μm (inner diameter 50 μm), outer diameter 150 μm (inner diameter 100 μm), outer diameter 200 μm (inner diameter 130 μm), etc. These are about the same thickness as the needles used by acupuncturists, and it is possible to produce needles up to 300 mm long.
The project will be commissioned to evaluate drugs using experimental animals in cooperation with local governments and facilities that allow animal experiments. In addition, we will conduct demonstration experiments with the cooperation of pharmaceutical companies and medical and pharmaceutical departments of universities.
With this device, the therapeutic effect is improved, the disease is cured quickly, and the healthy life span is extended. This will lead to the vitalization of the pharmaceutical industry as it can significantly reduce drug development costs and increase new drug candidates while reducing medical costs. (2017.5.10)
Conventional intravenous has the following problems.
- ①Patient’s problem: The infusion bag in held in a high position because the needle connected to the end of a long tube is inserted into the arm etc. and the liquid medicine from the infusion bag is fed into the body by natural fall due to gravity. The patient must therefore, rest quietly in bed or must roll around the stand with wheels when going to the bathroom.
- ②Hospital issues: The hospital has to check the amount of drip reduction many times through a nurse, which can cause labor shortages. In order to prevent the tube from becoming entangled or hurting the patient when the needle is pulled out, the nurse has to be extra cautious. In addition, precious empty floor (empty bed) will be filled.
- ③Challenges for manufacturers: Manufacturers are already in an unprofitable situation because of the low cost of infusion bags but high storage and transportation costs.
Mobile infusion solves these problems.
①Patient benefits: A rubber infusion device (with a weight of 10 g or less) can be simply attached to the arm, allowing freedom of movement. The pain is also reduced because the needle is thin.
②Hospital benefits: By using IoT technology with a drip quantity sensor and electronic board on the device, the patient’s location, dosage, etc. can be managed with one PC, and 100 people per nurse. It becomes possible to monitor patients. It also makes it easier to move patients during surgery and examinations, and increases the number of empty beds.
③Advantages of the manufacturer: It will be profitable as a business because it will be smaller, so it will not incur storage costs and transportation costs, and it will be a product with high added value.
The reason why this is possible is that, as with the mobile medication described above, overcoming the following two points is an important factor.
- A simple pump that could be controlled with ultra-fine liquid was needed but was not present
⇒Because the drip is a low-cost treatment, it was not possible to assign an expensive pump to each person. In addition, there was no pump (no pulsating flow, no vibration, low flow rate) and a chemical reservoir suitable for infusion.
- There was no thin needle with little pain when performing subcutaneous injections over a long period of time.
⇒When a normal needle is placed under the skin, the pain is strong, so a very fine needle with little pain is required. This eliminates the need to pierce blood vessels with needles, increasing the operability of doctors and nurses and the safety of patients.
Below is a schematic diagram of the device.
The scope of application of this device is widely considered.
- Home-care patients and dementia patients → Reduced medication burden for caregivers
- Child → If it is difficult to take medicine orally
- Livestock → Reduced producer burden
- Pets → Reduce owner’s burden
By extending this device to such fields, we can solve various problems. (2017.5.12)
Posted on this site as of 2017.9.1
English version created on 2019.9.1